PetVivo Holdings (NASDAQ: PETV) settles VetStem PrecisePRP® agreement
Rhea-AI Filing Summary
PetVivo Holdings, Inc. terminated its Exclusive License and Supply Agreement with VetStem, Inc. for the PrecisePRP® product line through a Termination and Settlement Agreement effective July 24, 2026. All exclusive rights under the prior license reverted to VetStem, remaining PrecisePRP® inventory transferred to VetStem, and the parties exchanged mutual releases covering substantially all claims arising under the license, fully resolving related disputes.
Under the settlement, PetVivo’s sole stated financial obligation is aggregate cash payments of $75,000, with $50,000 due within 14 days of the effective date and $25,000 due within 30 business days, plus any additional amount that may arise from an inventory reconciliation mechanism. A warrant held by VetStem to purchase 250,000 PetVivo common shares remains outstanding on its existing terms. The company states that this resolution allows it to concentrate resources on its proprietary technologies, including SPRYNG® with OsteoCushion® Technology, and broader strategic initiatives.
Positive
- None.
Negative
- None.
Filing Explained
The scheduled
Sources and calculations
- PetVivo Holdings Form 8-K (2026-07-28)
- PetVivo fiscal 2026 fourth-quarter fundamentals (2026-03-31)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $200,782 / ($812,382 / 90) = [object Object]
8-K Event Classification
Key Figures
Key Terms
Termination and Settlement Agreement regulatory
Exclusive License and Supply Agreement regulatory
inventory reconciliation mechanism financial
mutual releases regulatory
forward-looking statements regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What agreement did PetVivo Holdings (PETV) terminate with VetStem?
What are the key financial terms of PetVivo’s (PETV) settlement with VetStem?
How does the PetVivo (PETV) and VetStem settlement affect PrecisePRP® rights and inventory?
How does PetVivo (PETV) describe the strategic impact of the VetStem settlement?
On what date did the PetVivo (PETV) Termination and Settlement Agreement with VetStem become effective?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(g) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| OTCQX | ||||
| OTCID |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.02 Termination of a Material Definitive Agreement
On July 24, 2026 (the “Effective Date”), PetVivo Holdings, Inc. (the “Company”) entered into a Termination and Settlement Agreement (the “Settlement Agreement”) with VetStem, Inc. (“VetStem”), pursuant to which the parties agreed to terminate the Exclusive License and Supply Agreement, dated February 13, 2025, as amended (the “License Agreement”), and resolve all disputes arising under the License Agreement.
Pursuant to the Settlement Agreement, the License Agreement terminated effective July 24, 2026, subject only to certain specifically identified surviving provisions relating primarily to confidentiality, intellectual property ownership, dispute resolution, and certain other customary post-termination obligations. All exclusive rights previously granted to the Company under the License Agreement reverted to VetStem, ownership of the Company’s remaining PrecisePRP® Canine and PrecisePRP® Equine inventory transferred to VetStem, and the parties mutually released one another from substantially all claims arising under or relating to the License Agreement through the Effective Date, subject to the continuing obligations set forth in the Settlement Agreement. The Settlement Agreement fully and finally resolves all disputes between the parties arising under the License Agreement and eliminates all remaining financial obligations thereunder, except as expressly provided in the Settlement Agreement.
Pursuant to the Settlement Agreement, the parties agreed that, except for the payment obligations expressly set forth therein, all financial obligations arising under the License Agreement are fully satisfied, released and extinguished, including outstanding invoices, accrued royalty obligations, milestone payment obligations and other amounts that either party claimed may have been owed under the License Agreement. As a result, the Company’s sole remaining financial obligation under the Settlement Agreement is to make aggregate cash payments totaling $75,000, consisting of (i) $50,000 payable within fourteen (14) days following the Effective Date and (ii) $25,000 payable within thirty (30) business days following the Effective Date. The Settlement Agreement also provides for an inventory reconciliation mechanism pursuant to which the Company may be required to make an additional payment in the event the transferred inventory is less than the agreed minimum quantities specified in the Settlement Agreement. The specific amount payable in connection with any such inventory shortfall has been omitted from the filed exhibit because it is both immaterial to investors and competitively sensitive.
The Settlement Agreement further provides that the previously issued Common Stock Purchase Warrant issued by the Company to VetStem to purchase 250,000 shares of the Company’s common stock remains outstanding in accordance with its existing terms and was not terminated or modified by the Settlement Agreement.
The foregoing description of the Settlement Agreement does not purport to be complete and is qualified in its entirety by reference to the Settlement Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure
On July 28, 2026, PetVivo Holdings, Inc. (the “Company”) issued a press release announcing that it had entered into a Termination and Settlement Agreement with VetStem, Inc., pursuant to which the parties terminated their Exclusive License and Supply Agreement and resolved all outstanding disputes arising thereunder. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
This Current Report on Form 8-K, including the press release furnished as Exhibit 99.1, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the anticipated benefits of the Settlement Agreement, the orderly transition of customer, distributor and commercial activities, the Company’s ability to focus resources on its proprietary product portfolio and strategic initiatives, and other statements that are not historical facts. These statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others, the Company’s ability to satisfy its obligations under the Settlement Agreement, complete the transition activities contemplated thereby, continue the commercialization of its existing products, execute its business strategy, obtain regulatory approvals where required, maintain intellectual property protections, achieve market acceptance of its products, and the other risks described from time to time in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
The forward-looking statements contained herein speak only as of the date of this Current Report on Form 8-K, and the Company undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date hereof, except as required by applicable law.
Item 9.01 Financial Statements and Exhibits.
| (d) | Exhibits |
10.1
|
Termination and Settlement Agreement, dated July 24, 2026, by and between PetVivo Holdings, Inc. and VetStem, Inc. Certain identified information has been omitted because it is not material and is the type of information that the registrant customarily and actually treats as private or confidential.
|
| 99.1 | Press Release, regarding the Termination and Settlement Agreement, dated July 28, 2026 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PETVIVO HOLDINGS, INC. | ||
| Date: July 28, 2026 | By: | /s/ John Lai |
| Name: | John Lai | |
| Title: | Chief Executive Officer | |
Exhibit 99.1
5151 Edina Industrial Blvd., Suite 575, Minneapolis, MN 55439 | (952) 405-6216 | www.petvivo.com
PRESS RELEASE:
PETVIVO HOLDINGS ANNOUNCES TERMINATION AND SETTLEMENT AGREEMENT WITH VETSTEM
Agreement Resolves All Outstanding Matters and Completes Transition of PrecisePRP® Product Line
MINNEAPOLIS, July 28, 2026 — PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) working in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc., Cosmeta Corp and PetVivo AI, Inc. (collectively “PetVivo” or the “Company”), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for horses and companion animals, today announced that it has entered into a Termination and Settlement Agreement with VetStem, Inc., effective July 24, 2026.
Under the agreement, the parties have terminated their Exclusive License and Supply Agreement relating to the PrecisePRP® product line, resolved all matters arising under the parties’ prior Exclusive License and Supply Agreement, and established an orderly transition of the remaining PrecisePRP® inventory and related commercial activities. The Settlement Agreement further provides that, except for the payments expressly required thereunder, all financial obligations arising under the prior License Agreement have been fully satisfied and extinguished, including outstanding invoices, accrued royalty obligations, milestone payment obligations and other claims between the parties. The agreement includes mutual releases with respect to substantially all claims arising under the prior agreement, subject only to certain continuing obligations customary for agreements of this nature.
As a result of the comprehensive settlement, PetVivo’s sole remaining financial obligation under the Settlement Agreement is the payment of an aggregate of $75,000, consisting of two scheduled cash payments. The Settlement Agreement also includes an inventory reconciliation mechanism pursuant to which PetVivo may be required to make an additional payment if the transferred inventory is determined to be less than the agreed minimum quantities following the parties’ inventory verification process. The agreement further provides for the return of the remaining PrecisePRP® product inventory to VetStem. In addition, the Settlement Agreement confirms that the previously issued warrant held by VetStem to purchase 250,000 shares of PetVivo common stock remains in full force and effect in accordance with its existing terms.
“This agreement represents the successful conclusion of our commercial relationship with VetStem and allows both companies to move forward independently,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Most importantly, it enables PetVivo to devote its full attention and resources to advancing our proprietary technologies, including SPRYNG® with OsteoCushion® Technology, while continuing to execute our broader strategic growth initiatives.”
The Company has filed a Current Report on Form 8-K with the Securities and Exchange Commission describing the agreement in greater detail.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly owned subsidiaries PetVivo Animal Health, Inc., Cosmeta Corp and PetVivo AI Inc., is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protect the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG® with OsteoCushion® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, is currently available for commercial sale.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2026, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.